Skip to main navigation menu Skip to main content Skip to site footer

Vol. 12 No. 10 (2025)
International Multidisciplinary Journal for Research & Development

Articles

THE ROLE OF CHRONIC HEPATITIS C VIRUS IN THE DEVELOPMENT OF LIVER CIRRHOSIS AND CLINICAL OUTCOMES

Published 2025-10-20

  • Kaxarov Abdukaxar Nabijonovich

Kaxarov Abdukaxar Nabijonovich
Assistant Department of infectious diseases, Andijan State Medical Institute, Uzbekistan, Andijan

Abstract

Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver disease worldwide, culminating in significant morbidity and mortality. The progression from chronic hepatitis to cirrhosis is a complex, multifactorial process that represents a critical turning point in the natural history of the disease. This article provides a comprehensive review of the pivotal role of HCV in the pathogenesis of liver cirrhosis, detailing the virological and host factors that influence disease progression. We explore the clinical manifestations and diverse outcomes of HCV-related cirrhosis, including the development of decompensated liver disease, hepatocellular carcinoma (HCC), and extrahepatic manifestations. Furthermore, we discuss the diagnostic modalities, management strategies, and the transformative impact of direct-acting antiviral (DAA) therapy on preventing cirrhosis and improving patient outcomes. Despite the success of DAAs, challenges remain in managing patients with pre-existing advanced fibrosis or cirrhosis, highlighting the continued importance of understanding the long-term sequelae of this infection. This review synthesizes current knowledge to provide a detailed perspective on the clinical challenges and management of HCV-induced cirrhosis.

Keywords

Hepatitis C Virus, Liver Cirrhosis, Chronic Hepatitis, Hepatocellular Carcinoma, Direct-Acting Antivirals, Liver Fibrosis, Portal Hypertension, Disease Progression.

PDF

References

  1. (Formatted in APA 7th Edition style. Note: Hyperlinks are provided where available through DOIs.)
  2. World Health Organization. (2023). Hepatitis C. WHO. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
  3. Liang, T. J., & Ghany, M. G. (2013). Current and future therapies for hepatitis C virus infection. New England Journal of Medicine, 368(20), 1907–1917. https://doi.org/10.1056/NEJMra1213651
  4. Thein, H. H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008). Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology, 48(2), 418–431. https://doi.org/10.1002/hep.22375
  5. Poynard, T., Bedossa, P., & Opolon, P. (1997). Natural history of liver fibrosis progression in patients with chronic hepatitis C. The Lancet, 349(9055), 825–832. https://doi.org/10.1016/S0140-6736(96)07642-8
  6. Friedman, S. L. (2008). Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiological Reviews, 88(1), 125–172. https://doi.org/10.1152/physrev.00013.2007
  7. Bochud, P. Y., Cai, T., Overbeck, K., Eijsink, R., Bibert, S., Lagging, M., ... & Negro, F. (2009). Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of Hepatology, 51(4), 655–666. https://doi.org/10.1016/j.jhep.2009.05.016
  8. van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J. F., Lammert, F., ... & Janssen, H. L. (2012). Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA, 308(24), 2584–2593. https://doi.org/10.1001/jama.2012.144878
  9. Morgan, R. L., Baack, B., Smith, B. D., Yartel, A., Pitasi, M., & Falck-Ytter, Y. (2013). Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Annals of Internal Medicine, 158(5_Part_1), 329–337. https://doi.org/10.7326/0003-4819-158-5-201303050-00005
  10. D'Ambrosio, R., Aghemo, A., Rumi, M. G., Ronchi, G., Donato, M. F., Paradis, V., ... & Colombo, M. (2012). A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus-related cirrhosis. Hepatology, 56(2), 532–543. https://doi.org/10.1002/hep.25606
  11. Ioannou, G. N., Green, P. K., & Berry, K. (2017). HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. Journal of Hepatology, 68(1), 25-32. https://doi.org/10.1016/j.jhep.2017.08.030
  12. European Association for the Study of the Liver. (2018). EASL Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology, 69(2), 461–511. https://doi.org/10.1016/j.jhep.2018.03.026
  13. Singal, A. G., & El-Serag, H. B. (2015). Hepatocellular carcinoma from epidemiology to prevention: a complex puzzle. Clinical Liver Disease, 20(4), 1-13. https://doi.org/10.1002/cld.508

Downloads

Download data is not yet available.